These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33049447)

  • 1. B7-H3 expression in upper tract urothelial carcinoma associates with adverse clinicopathological features and poor survival.
    Koyama Y; Morikawa T; Miyama Y; Miyakawa J; Kawai T; Kume H; Sawabe M; Ushiku T
    Pathol Res Pract; 2020 Dec; 216(12):153219. PubMed ID: 33049447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
    Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Positivity Associated With Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma.
    Smith ME; Farahani SJ; Chao T; Palmer M; Arriola A; Lal P
    Am J Clin Pathol; 2020 Nov; 154(6):802-810. PubMed ID: 32864684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
    Reis H; Serrette R; Posada J; Lu V; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Iyer G; Funt SA; Teo MY; Rosenberg JE; Bajorin DF; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Am J Surg Pathol; 2019 Jul; 43(7):920-927. PubMed ID: 31135485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X; Hu C; Zhang Z; Zhu Y; Liu W; Zheng B; Feng X; Lu H
    Endocr Pathol; 2024 Sep; 35(3):230-244. PubMed ID: 39102163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
    Mizuno T; Kamai T; Tsuzuki T; Nishihara D; Kijima T; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2022 Mar; 71(3):565-578. PubMed ID: 34275008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma.
    Makise N; Morikawa T; Nakagawa T; Ichimura T; Kawai T; Matsushita H; Kakimi K; Kume H; Homma Y; Fukayama M
    Hum Pathol; 2016 Apr; 50():62-9. PubMed ID: 26997439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
    Krabbe LM; Heitplatz B; Preuss S; Hutchinson RC; Woldu SL; Singla N; Boegemann M; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Rapoport LM; Glybochko PV; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Xylinas E; Margulis V
    J Urol; 2017 Dec; 198(6):1253-1262. PubMed ID: 28668287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
    Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF
    Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.
    Miyama Y; Morikawa T; Miyakawa J; Koyama Y; Kawai T; Kume H; Fukayama M
    Cancer Med; 2018 Sep; 7(9):4330-4338. PubMed ID: 30062756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study.
    Mathieu R; Klatte T; Margulis V; Karam JA; Rouprêt M; Seitz C; Karakiewicz PI; Fajkovic H; Wood CG; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Bensalah K; Lotan Y; Rink M; Kluth LA; Scherr DS; Robinson BD; Shariat SF
    Urol Oncol; 2015 Nov; 33(11):495.e15-22. PubMed ID: 26228160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
    Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
    Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
    Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
    Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
    Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
    Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
    Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
    Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.